{
    "nct_id": "NCT02403505",
    "official_title": "Conducting an Early Phase Clinical Trial to Assess for CEA Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of CEA Positive Rectal Cancer Patients.",
    "inclusion_criteria": "* Clinical Rectal Cancer Diagnosis Stage 0 - IIA\n* Clinical Rectal Cancer Diagnosis without symptoms\n* Clinical Rectal Cancer Diagnosis without metastasis\n* Positive testing CEA by blood-drawing\n* TB negative participant is negative IGRA blood test with TB antigens.\nHealthy volunteers allowed\nMust have minimum age of 24 Years\nMust have maximum age of 64 Years",
    "exclusion_criteria": "* Pregnant\n* Thrombosis\n* Allergy\n* TB positive participant is positive IGRA blood test with TB antigens.\n* Symptoms of rectal cancer\n* Metastasis of rectal cancer\n* Evidence of critical illness",
    "miscellaneous_criteria": "Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of CEA positive rectal cancer patients.\n\n20 CEA Positive Rectal Cancer Patients"
}